| Theme | Perspective for Chemotherapy in Gastrointestinal Malignancy Based on Current Evidence | |
|---|---|---|
| Title | New Strategies for Treatment of Unresectable Colorectal Cancer | |
| Publish Date | 2013/03 | |
| Author | Daisuke Sakai | Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine |
| Author | Taroh Satoh | Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine |
| Author | Toshihiro Kudo | Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine |
| Author | Hideshi Ishii | Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine |
| Author | Yuichiro Doki | Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine |
| Author | Masaki Mori | Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine |
| [ Summary ] | The survival of patients with unresectable colorectal cancer has been extended through the advent of effective key drugs. A point for the choice of first-line treatments is relevant to treatment goals. These goals depend on tumourbiology, as well as patient-related or drug-related factors. One of the principal treatment strategies is "conversion chemotherapy" in hope of converting unresectable or borderline resectable metastatics. Another strategy is "sequential chemotherapy" for tumors of which progression is likely to be slow or asymptomatic. It was also shown that, by employing the strategy known as "BBP (Bevacizumab Beyond Progression)", prolonged survival can be obtained. With the advent of the new drugs, regorafenib and aflibercept, the number of starategies for treatment of unresectable colorectal cancer will increase. |
|